Silodosin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Silodosin
- Silodosin: From Benign Prostatic Hyperplasia/LUTS to Ambras Type Hypertrichosis Universalis Congenita
Silodosin: From Benign Prostatic Hyperplasia/LUTS to Ambras Type Hypertrichosis Universalis Congenita
One-Sentence Summary
Silodosin is a highly selective alpha-1A adrenergic receptor antagonist, pharmacologically classified for benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). The TxGNN model predicts a possible association with Ambras type hypertrichosis universalis congenita, a rare congenital hair-overgrowth disorder, but this prediction is currently supported by zero clinical trials and zero literature, and the model’s own mechanistic rationale explicitly states there is no known biological pathway connecting the drug to this disease.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in the structured data provided; the drug class (alpha-1A antagonist) is typically indicated for BPH/LUTS |
| Predicted New Indication | Ambras type hypertrichosis universalis congenita |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| EU Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (structured original_moa field is a data gap). Based on the mechanistic notes attached to this evidence pack, Silodosin is understood to be a highly selective alpha-1A adrenergic receptor antagonist, a class typically used to relax smooth muscle in the prostate and bladder neck for BPH/LUTS.
For the top-ranked predicted indication, the model’s own mechanistic assessment states there is no known interaction between alpha-1A receptor antagonism and the genetic pathways implicated in congenital hypertrichosis (e.g., the 8q24 duplication region), and concludes there is no reasonable mechanistic support for this repurposing hypothesis. This is a case where the embedding-based similarity score is high, but the accompanying biological rationale explicitly contradicts plausibility.
This pattern repeats across the full candidate list: all 10 predicted indications in this evidence pack (ranks 1–10, covering hair/skin disorders, craniofacial malformation syndromes, and pulmonary/cardiovascular conditions) are scored L5 (model prediction only) with Hold recommendations, and for 9 of the 10, the rationale text explicitly states “no mechanistic link” (無機轉關聯). The one partial exception, chronic thromboembolic pulmonary hypertension (rank 10), notes a theoretical vascular-tone connection but immediately qualifies it as weak, since Silodosin’s high alpha-1A selectivity was specifically designed to minimize systemic vascular effects (to avoid orthostatic hypotension).
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
(Note: literature was returned for the rank-3 candidate, “malformation syndrome with odontal and/or periodontal component,” but all 20 records are general periodontitis research that do not mention Silodosin or alpha-1 adrenergic pathways — these appear to be keyword-overlap artifacts rather than drug-specific evidence, and are not included here as they do not pertain to the top-ranked indication.)
EU Market Information
No marketing authorizations are recorded for this drug in the provided data (total_licenses: 0, market status: Not marketed).
Safety Considerations
Please refer to the SmPC for safety information.
Important gap: the drug label (warnings/contraindications) has not yet been retrieved from the regulatory source (severity: Blocking) — this currently prevents any formal safety pre-screening (S1 stage).
Conclusion and Next Steps
Decision: Hold
Rationale:
- All 10 predicted indications are L5 (AI prediction only), with no supporting clinical trials or relevant literature.
- The model’s own mechanistic rationale for the top-ranked indication states there is no known biological pathway connecting Silodosin to hair-growth regulation — this is a case of high similarity score without plausibility.
- The drug is not currently marketed in the target jurisdiction (0 authorizations), and core safety data (warnings/contraindications) is a Blocking data gap that prevents any downstream safety evaluation.
To proceed, the following is needed:
- TFDA/regulatory label data (warnings, contraindications) — currently Blocking
- Confirmed MOA data from DrugBank (currently a High-severity gap)
- An independent, disease-specific literature search (the current literature for rank 3 is not usable — it lacks any drug-specific relevance)
- If pursuing any candidate further, a documented biological mechanism linking alpha-1A antagonism to the target disease, since none currently exists in this pack
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.